IL2RA and melanoma: At least two IL-2-CD25 fusion proteins, ALKS 4230, targeting the intermediate-affinity IL-2R, and IL-2/CD25 transdimers, targeting the high-affinity IL-2R, have been described with improved antitumor efficacy in mouse B16-F10 melanoma (71, 102, 123).